BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Synlogic (SYBX)SynlogicClinical readout

Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass. , Feb.

Related news

SGMTSagimet Biosciences2026-04-27 11:00 EST

Sagimet Biosciences Provides Strategic and Corporate Updates

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

ALTAltimmune2026-07-28 11:00 EST

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

VANIVivani Medical2026-08-06 12:00 EST

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

MNKDMannKind2026-06-23 13:00 EST

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

SGMTSagimet Biosciences2026-05-27 11:00 EST

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.20 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States